

10-07-02

1614

PHA 4145.4 (2918/3A)
PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

OCT 10 2003

RECEIVED

Application of S. Gregory et al. Art Unit 1614

Serial No. 10/617,222

Filed July 10, 2003

Confirmation No. to be assigned

For IMMUNOSUPPRESSIVE EFFECTS OF ADMINISTRATION OF A
CYCLOOXYGENASE-2 INHIBITOR, A LEUKOTRIENE B4 RECEPTOR
INHIBITOR AND A CYCLOSPORIN

October 6, 2003

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VIRGINIA 22313-1450

SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicant submits the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.

The references listed on the attached PTO/SB/08A have been previously submitted in parent application Serial No. 09/659,299, filed September 12, 2000, and, therefore, in accordance with MPEP 609, are not being provided at this time.

Respectfully submitted,

Kathryn J. Doty, Reg. No. 40,593
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

KJD/cms

Express Mail Label No. EV 324378838 US

RECEIVED

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/617,222
				Filing Date	07-10-2003
				Confirmation Number	To Be Assigned
				First Named Inventor	S. Gregory
				Group Art Unit	1614
				Examiner Name	B. Kwon
Sheet	1	of	5	Attorney Docket No.	2918/3A (4145.4)

U.S. PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	1	4,595,699		Terada et al.	06-17-1986
	2	4,871,771	B1	Gleason et al.	10-03-1989
	3	4,889,935	B1	Musser	12-26-1989
	4	4,923,891	B1	Deason et al.	05-08-1990
	5	4,970,234	B1	Djuric et al.	11-13-1990
	6	5,210,208	B1	Huang et al.	05-11-1993
	7	5,212,198	B1	Djuric et al.	05-18-1993
	8	5,232,948	B1	Huang et al.	08-03-1993
	9	5,246,965		A. Main	09-21-1993
	10	5,256,686	B1	Konno et al.	10-26-1993
	11	5,272,178	B1	Mueller et al.	12-21-1993
	12	5,310,951	B1	Djuric et al.	05-10-1994
	13	5,344,991		Reitz et al.	09-06-1994
	14	5,366,982	B1	Dereu et al.	11-22-1994
	15	5,380,738		Norman et al.	01-10-1995

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08A

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/617,222
Filing Date	07-10-2003
Confirmation Number	To Be Assigned
First Named Inventor	S. Gregory
Group Art Unit	1614
Examiner Name	B. Kwon

TECH CENTER 1600 2003

OCT 10 2003

RECEIVED

Sheet	2	of	5	Attorney Docket No.	2918/3A (4145.4)
-------	---	----	---	---------------------	------------------

	16	5,380,740	B1	Djuric et al.	01-10-1995
	17	5,384,318		Eggler et al.	01-24-1995
	18	5,393,790		Reitz et al.	02-28-1995
	19	5,434,178	B1	Talley et al.	07-18-1995
	20	5,446,035	A	Neef et al.	09-29-1995
	21	5,466,863	B1	Heidt et al.	11-14-1995
	22	5,474,995	B1	Ducharme et al.	12-12-1995
	23	5,521,207	A	Graneto	05-28-1996
	24	5,633,272		Talley et al	05-27-1997
	25	5,700,816		Isakson et al.	12-23-1997
	26	5,916,905	A	Weier et al.	06-29-1999
	27	6,096,728	A	Collins et al.	08-01-2000

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
	28	EP	485 111	A2	Imperial Chemical Industries PLC	05-13-1992	
	29	DE	4228201	A1	Schering AG Berlin and Bergkamen	03-03-1994	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



RECEIVED

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/617,222
				Filing Date	07-10-2003
				Confirmation Number	To Be Assigned
				First Named Inventor	S. Gregory
				Group Art Unit	1614
				Examiner Name	B. Kwon
Sheet	3	of	5	Attorney Docket No.	2918/3A (4145.4)

	30	WO	94/02448	A1	The Wellcome Foundation LTD.	02-03-1994	
	31	WO	94/04522	A1	Schering Aktiengesellschaft	03-03-1994	A
	32	WO	94/13635	A1	Merck Frosst Canada Inc.	06-23-1994	
	33	WO	94/15932	A1	G.D. Searle & Co.	07-21-1994	
	34	WO	94/20480	A1	Merck Frosst Canada Inc.	09-15-1994	
	35	WO	94/26731	A1	Merck Frosst Canada Inc.	11-24-1994	
	36	WO	94/27980	A1	G.D. Searle & Co.	12-8-1994	
	37	WO	95/00501	A2	Merck Frosst Canada Inc.	01-05-1995	
	38	WO	95/15316	A1	G.D. Searle & Co.	06-08-1995	
	39	WO	96/03385	A1	G.D. Searle & Co.	02-08-1996	
	40	WO	96/03387	A1	G.D. Searle & Co.	02-08-1996	
	41	WO	96/03388	A1	G.D. Searle & Co.	02-08-1996	
	42	WO	96/06840	A1	Merck Frosst Canada Inc.	03-07-1996	
	43	WO	96/41645	A1	G.D. Searle & Co.	12-27-1996	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					T ⁶
	44	BADGER et al., IMMUNOPHARM, 4, 149 (1982).					
	45	BARTLETT et al., Drugs Exptl. Clin. Res., 15, 521 (1989).					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/617,222
				Filing Date	07-10-2003
				Confirmation Number	To Be Assigned
				First Named Inventor	S. Gregory
				Group Art Unit	1614
				Examiner Name	B. Kwon
Sheet	4	of	5	Attorney Docket No.	2918/3A (4145.4)

46	BASMAJIAN et al., "Acute Back Pain and Spasm, A Controlled Multicenter Trial of Combined Analgesic and Antispasm Agents." Acute Back Pain, 1988.
47	BEAVER, Am. J. Med. 77, 38 (1984)
48	BELCHER et al., "Circulating Concentrations of Histamine, Neutrophil Chemotactic Activity, and Catecholamines During the Refractory Period in Exercise-Induced Asthma." The Journal of Allergy and Clinical Immunology, 1988, pp. 100-110, Vol. 81, No. 1.
49	BRAUN et al., Proc. Am. Soc. Clin. Oncol., 4, 21 Meeting, 223 (1985).
50	BREEDVELD, Scan. J. Rheumatol, 23 (Supp. 100), 31 (1994).
51	CAPLUS abstract 1996:225716, Nickerson-Nutter et al., The effects of Leukotriene ... March. 1996
52	CAPLUS 1996:582169, Zhang Wenyu et al., Tumor Necrosis, Jun. 1996.
53	CHANG et al., "Prevention of ocular Inflammation by Matrine, Prednisolone, and Cyclooxygenase and Lipoxygenase Inhibitors." Acta Pharmacologica Sinica, 1991, pp. 121-125, Vol. 12, No. 2.
54	FIMIANI et al., EOS-Revista di Immunologia and Immunofarmacologia, 13, 58 (1993).
55	FOSSALUZZA et al., "Combined Therapy with Cyclobenzaprine and Ibuprofen in Primary Fibromyalgia Syndrome." Int. J. Clin. Pharm. Res., 1992, pp. 99-102, Vol. XII, No. 2.
56	FUNG-LEUNG et al., Transplantation, 60, 362 (1995).
57	GREENWALD, et al., "Tetracyclines Suppress Matrix Metalloproteinase Activity in Adjuvant Arthritis and in Combination with Flurbiprofen, Ameliorate Bone Damage." The Journal of Rheumatology, 1992, pp. 927-938, Vol. 19, No. 6.
58	GUTH et al., Pro. Natl. Acad. Sci. USA, 91, 12308 (1994).
59	HUGHES et al., Dermatology, 184, 54 (1992).
60	LATTER et al., J. Surg. Res., 43, 246 (1987).
61	LIGHTMAN and P. WATSON, Am. J. Ophthalmol., 108, 95 (1989).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/617,222
				Filing Date	07-10-2003
				Confirmation Number	To Be Assigned
				First Named Inventor	S. Gregory
				Group Art Unit	1614
				Examiner Name	B. Kwon
Sheet	5	of	5	Attorney Docket No.	2918/3A (4145.4)

	62	POLLOCK et al., "Pharmacokinetics analysis of cyclosporine in adjuvant arthritic rats", Drug Metabolism and Disposition, 17(6), 595-9, abstract, 1989.	
	63	SEIDEMAN et al., Acta Orthop. Scand., 64, 285 (1993).	
	64	SEIFERT and ENGLER, Curr. Med. Res. Opin., 7, 38 (1980).	
	65	SHAW and GREATORREX, Adv. Prostaglandin, Thromboxane, Leukotriene Res., 13, 219 (1985).	
	66	SHELBY et al., Transplantation Proc, 19, 1435 (1987).	
	67	STEWART et al., Clin. Pharmacol. Ther., 47, 540 (1990).	
	68	TARAYRE et al., Arzneim.-Forsch./Drug Res., 40, 1125 (1990).	
	69	TRAMPOSCH, Inflammation, 17, 531 (1993).	
	70	TEICHER et al., Cancer Chemother. Pharmacol, 33, 515 (1994).	
	71	WILLKENS and SEGRE, Arthritis Rheum, 19, 677 (1976).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.